Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials

Published 28 July 2020, after more than 20 years of median cumulative follow-up, WHI trials find prior randomized use of CEE alone, compared with placebo, among women who had a previous hysterectomy, was significantly associated with lower breast cancer incidence and lower breast cancer mortality, whereas prior randomized use of CEE plus MPA, compared with placebo,…

Details

EMAS clinical guide on menopause symptom management in women with dyslipidemias

Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile. Published in Maturitas EMAS  has  produced an evidence-based clinical guide evaluating the effects on the lipid profile both of menopausal hormone therapy and of non-estrogen-based treatments for menopausal symptoms. Click here to read more. Menopause…

Details

Message from EMAS

The European Menopause and Andropause Society (EMAS) expresses it sympathy with those affected by the outbreak of COVID-19. We express our solidarity with the medical teams working around the clock to treat and contain the virus. COVID-19 has thankfully caused minimum disruption to the ongoing activities of EMAS. Our Congress is biennial (next edition 2021)…

Details